PARIS, France and TARRYTOWN, NY, USA I March 8, 2025 I Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent ...
Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under ...
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD . Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback